DUBLIN, Chikumi 26, 2023- Chirevo "Yakarambidzwa Peptide Musika Wemishonga - Yepasirese uye Yedunhu Ongororo: Tarisa paPeptide Mhando, Zvigadzirwa uye Dunhu Ongororo - Ongororo uye Forecast, 2024-2040 ″.
Mushure mekutanga musika kuvhurwa kwekutanga kurambidzwa peptide mushonga, musika wepasi rose wezvinodhaka unofungidzirwa kukura kubva 2024 kusvika 2040. Saizi yemusika inotarisirwa kusvika $60M muna 2024 uye $17.38B muna 2040, iine CAGR ye38.94% pamusoro. iyo yekufanotaura nguva 2025-2040.
Musika wepasi rose wakatemerwa peptide mushonga unotarisirwa kuona kukura kwakakura panguva yekufanotaura kubva muna 2025 kusvika 2040, ichisundwa muchikamu chikuru nevimbiso yekubuda kutsva kwepombi yepeptide iyo isingachaganhurirwe kune zvinangwa zvekugamuchira.Kufambira mberi mune tekinoroji yemakemikari, kufambira mberi mukushambadzira kwesynthetic peptide therapeutics mumakore achangopfuura, uye mitengo inokwanisika inowanikwa neaya ma biomolecules muzvirwere zvakasiyana siyana zvimwe zvinhu zvinowedzera mukukura kuri kufungidzirwa panguva yekufanotaura.
Kuongororwa kwekukanganisa kwenguva pfupi uye kwenguva refu kunoitwa pazvinhu zvinonyanya kukanganisa musika, zvinoti, vatyairi, zvipingaidzo nemikana.Iyo pfupi-yenguva yekuongorora inotarisa iyo nguva 2020-2025 uye iyo yakareba-yenguva yekuongorora inofunga iyo nguva 2026-2040.
Kubudirira kwakakosha uye marongero akatorwa nevamwe vevatambi vakakosha mumusika uyu akaverengerwa mukukanganisa ongororo yekuongorora.Pamusoro pezvo, izvi zvakakosha zviitiko zvinoongororwa kuti unzwisise mikana yeramangwana yekubatanidza matekinoroji epamberi kuti uwane mibairo yepamusoro.Pamusoro pezvo, kubvumidzwa uye kutangwa kwemakambani uye masangano epatent anotariswawo pakuongorora masimba emusika wepasi rose wepeptide-inorambidzwa peptide mishonga.
Demand Factors uye Constraints Izvi zvinotevera zvinhu zvinodiwa zvemusika wepasi rose wePeptide Dependence Inhibitors:
4 Market Overview 4.1 Nhanganyaya 4.1.1 Mamiriro uye Magadzirirwo ePeptides Anorambidzwa 4.1.2 Mhando dzeRestricted Peptides 4.2 Evolution of Restricted Peptides 4.3 Kugadzirwa kweRestricted Peptides seDhika 4.4 Potential Therapeutic Areas 4.5 Value Value Region Trends. ) ) 4.7 Mafambiro akakosha eindasitiri munzira yekusuma 4.8 Mafambiro akakosha eindasitiri - kufambira mberi kwetekinoroji 4.9 Saizi yemusika iripo uye kugona kukura, USD bhiriyoni, 2024-2040 uye kuvandudzwa kwemakambani anogadzira zvisingabvumirwe-kushandisa peptide mishonga.
5 Zvinhu zvemapeptide akaganhurirwa 5.1 Zvivakwa zvepeptides akaganhurirwa 5.2 Synthesis yeanorambidzwa peptides 5.2.1 Chemical ligation yepeptides uye bridging 5.2.2 Chemical ligation yepeptides kune scaffolds (CLIPS) 5.2.3 Plaptide Platide 5.2. kuwanikwa (5.2.5 Liquid-Phase Peptide Synthesis (LPPS) 5.2.6 Solid-Phase Peptide Synthesis (SPPS) 5.3 Advans in Peptide Technology 5.3.1 Peptide Synthesis Uchishandisa Microfluidics 5.3.2 Solid-Phase Peptide Synthesis Uchishandisa4. Sarudza System
6 Indasitiri Data 6.1 Overview 6.2 Nyaya dzine Regulatory Kubvumirwa Nzira dzeRestricted Peptides 6.3 Regulatory Scenarios Restricted Peptides 6.4 US Regulatory Zvinodiwa uye Structure 6.4.1 Clinical Trial Authorization 6.4.2 Marketing Sub. mutemo 6.5 European zvinodiwa pamutemo uye hwaro 6.5.1 EMA rezinesi chikumbiro muitiro 6.5.2 Centralized maitiro 6.5.3 Decentralized maitiro 6.5.4 Mutual recognition maitiro 6.5.5 National maitiro 6.6 Mutemo zvinodiwa uye hurongwa muAsia -Pacific nharaunda 6.6.1 Zvinodiwa nemutemo uye chimiro muJapan 6.7 Mamiriro ekudzorera 6.7.1 Mamiriro ekudzorera chirwere che autoimmune 6.7.2 Mamiriro ekudzorera kenza.
7 Market Dynamics 7.1 Impact Analysis 7.2 Market Factors 7.2.1 Yakawedzera Binding Affinity and Cellular Uptake 7.2.2 Kugadziridzwa Kwekashoma Synthetic Approaches 7.2.3 Kuganhurirwa kweConventional Peptides 7.2.4 Kuwedzera kweHomwe yePublic uye Yakavanzika 2 Kupa mari yeHurumende neYakavanzika 7.2. .4 .2 Kupihwa mari nemakambani akanyorwa 7.2.4.3 Mari nemasangano ehurumende 7.3 Zvipingamupinyi zvemusika 7.3.1 Kuwedzera makwikwi e biologics 7.3.2 Ngozi ye immunogenic effects uye sub-optimal properties yeADME 7.4 Mikana yemusika 7.4.1 Mapeptides mashoma mukuwanikwa kwezvinodhaka 7.4.2 Various applications nervous system uye cancer kurapwa
8 Mamiriro emakwikwi 8.1 Maonerwo emamiriro emakwikwi 8.1.1 Zviitiko zvakakosha 8.1.2 Zviitiko zvinotemerwa nemutemo 8.1.3 Kubatanidzwa nekutorwa kwemari
9 Musika wepasi rose wekudzora peptide mishonga (nemirayiridzo), mln USD, 2024–2040 9.1 Clinical Trial Design yeKudzora Peptide Therapies 9.1.1 Inogona Phase II Therapies II) 9.1.2.3 Efficacy, Safety, and Tolerability Data (Stage 1) 9. .2.4 Nonclinical Zvidzidzo zveBT5528 9.1.3 PN-9439.1.3.1 Chigadzirwa Chekutanga 9.1.3.2 Zvidzidzo zvekugadzira (Chikamu 2) 9.1.3.3 Kushanda, kuchengetedzwa uye kushivirira data (Phase II) 9.1.4 PN-2319.1.4. 4.2 Chidzidzo chekugadzira (Phase IIb) 9.1.4.3 Kushanda, kuchengetedzwa uye kushivirira data (Phase IIb) 9.1.5 Rusfertide (PTG-300) 9.1.5.1 Chigadzirwa chepamusoro 9.1.5.2 Chidzidzo chekugadzira (Chikamu II) 9.1.5.3 Kubudirira, kuchengeteka uye kuchengetedzwa data yekushivirira (Phase IIa) 9.1.6 Inogona Chikamu III mishonga 9.1.7 Zilukoplan (RA101495) 9.1.7.1 Chigadzirwa chidimbu 9.1.7.2 Chidzidzo chekugadzira (Chikamu III) 9.1.7.3 Kushanda, kuchengetedzwa uye kushivirira data (Chikamu III.7.7.) 49. Pharmacokinetic uye pharmacodynamic profile yeZilucoplan (Phase I) 9.1.8 Rusfertide (PTG- 300) 9.1.8.1 Chigadzirwa chepamusoro 9.1.8.2 Chidzidzo chekugadzira (Phase III) 9.1.8.3 Kubudirira, kuchengeteka uye kushivirira data (Phase II) ye9.2 Analysis ye9. kusimudzira masimba emusika wepasi rose wemishonga inorambidzwa peptide, USD miriyoni, 2024-2040 kubudirira 9.2.2.2 Mutengo wekugadzira API (CDMO)
10 Musika wepasi rose wemishonga ine shoma peptide chiito (nepeptide rudzi), US $ mln, 2024-2040 yakabatana peptide (DRP))
. .3.1 API Production (Outsourcing) Mutengo 11.1.4 PN-94311.1.4.1 API Production (Outsourcing) 11.1.4.2 API Demand Forecast 2024-2040
Nguva yekutumira: Jul-06-2023